Skip to content

Section archive

Page 2 of 4

H1N1

Dr. Mercola reports that GlaxoSmithKline asked Canadian officials to hold back one 172,000-dose lot of its Arepanrix H1N1 vaccine while it investigates anaphylaxis reported in about one of 20,000 recipients, against a usual rate of one in 100,000.

7 min read

66 stories